SARS-CoV-2 Pseudoviral Particles, Delta Variant (Indian B.1.617.2)
|
Catalog Number:
SCV2-PsV-Delta
|
|
SARS-CoV-2 Pseudoviral Particles, replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein (the Indian B.1.617.2 variant). (Mobile users please click "View Full Site" for details)
|
Detailed Description
Keyword: coronavirus, SARS, SARS-Cov, SARS-COV-2, covid19, covid-19, SARS pseudovirus, sars-cov-2 pseudovirus, sars-cov-2 spike, MLV, ace2, B.1.351, covid South Africa variant
|
SCV2-PsV-Delta
|
|
Name
|
SARS-CoV-2 Pseudoviral Particles, Delta Variant (Indian B.1.617.2)
|
|
Description
|
The SARS-CoV-2 Pseudoviral Particles are replication-deficient Maloneymurine leukemia virus (MLV or MuLV) pseudotyped with the SARS-CoV-2 spike protein of the Delta variant (Indian B.1.617.2) (also named 20A/S:478K, VUI-21APR-02) (GISAID accession # EPI_ISL_2020954).
MLV-based virus system is a better choice than HIV-based lentivirus system for making pseudoviral particles in regards of lab safety and product quality. Gag-Pol is the only component from MLV.
|
|
Applications
|
Our Pseudovirus Particles generate robust chemiluminescent signals in cell assays when coupled with our firefly luciferase assay kit (Catalog # CA-L165), useful for 1) screening potential inhibitors to block SARS-CoV-2 entry and viral protein; 2) measuring the activity of and screening for neutralizing antibody against SARS-CoV-2.
|
|
Size
|
5 ml, for one multi-well plate. Pseudoviral particles per mL ~ 1.0E+08
|
|
Storage
|
-70oC. Shipped on dry ice.
|
|
Note
|
1. Amenable to HTS format (96-well, 384-well and 1536-well format).
2. HEK293-hACE2 stable cell lines are available seperately (Cat.# CL-hACE2-001, CL-hACE2-002)
|
|
For Downloading
|
==>> DATA SHEET ==>> SAFETY DATA SHEET
|
Our SARS-CoV-2 pseudovirus products have been used in a lot COVID research work. Here are a few citations:
1) AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo. October 13, 2021.
2) A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerging Microbes & Infections, May 2021.
3) Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. Vaccines, Feb. 2021.
4) Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection. Clinical Infectious Diseases, Sept. 2020.
5) Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2. Biomedicines 2022, 10(12), 3274
|
|
|